Open AccessComparison of Her2/Neu Oncoprotein in Serum and Tissue Samples in Women with Breast Cancer
Author(s) -
Rakesh Pokhrel,
Binod Kumar Yadav,
Nisha Sharma,
Vijay Sharma,
Eans Tara Tuladhar,
Mithileshwer Raut,
Aseem Bhattarai,
Raju Kumar Dubey,
Apeksha Niraula,
Akash Mishra,
Uttam Budhathoki
Publication year - 2022
Publication title -
asian pacific journal of cancer prevention
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.512
H-Index - 75
eISSN - 2476-762X
pISSN - 1513-7368
DOI - 10.31557/apjcp.2022.23.2.429
Subject(s) - her2/neu , immunohistochemistry , breast cancer , medicine , estrogen receptor , histopathology , cancer , trastuzumab , immunoassay , antibody , pathology , oncology , immunology
Human Epidermal Growth Factor Receptor 2 (HER2/neu) is one of the most extensively studied proto-oncogens in breast cancer patients. Accurate and timely assessment of the HER2/neu over expression is pivotal for the identification of breast cancer patients that could benefit from HER2-targeted therapy. The present study was undertaken to investigate the diagnostic utility of serum HER2/neu testing by chemiluminescent immunoassay (CLIA) in breast cancer patients and compare it with the immunohistochemistry (IHC) method of HER2/neu expression.